NYSE · JNJHealthcarePharmaceuticals

Johnson & Johnson financials

$267.57−1.61%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

Fiscal yearFY25
Dec 28
FY24
Dec 29
FY23
Dec 31
FY22
Jan 1
FY21
Jan 2
FY20
Jan 3
FY19
Dec 29
FY18
Dec 30
FY17
Dec 31
FY16
Jan 1
Revenue$94.19B$88.82B$85.16B$79.99B$78.74B$82.58B$82.06B$81.58B$76.45B$71.89B
Gross profit$63.94B$61.35B$58.61B$55.39B$55.34B$54.16B$54.50B$54.49B$51.01B$50.10B
Gross margin67.9%69.1%68.8%69.3%70.3%65.6%66.4%66.8%66.7%69.7%
Operating income$25.29B$20.80B$21.21B$19.95B$19.83B$19.49B$19.81B$19.80B$18.18B$20.37B
Net income$26.80B$14.07B$35.15B$17.94B$20.88B$14.71B$15.12B$15.30B$1.30B$16.54B
Net margin28.5%15.8%41.3%22.4%26.5%17.8%18.4%18.8%1.7%23.0%
Diluted EPS$11.03$5.79$13.72$6.73$7.81$5.51$5.63$5.61$0.47$5.93
EBITDA$33.02B$28.38B$29.18B$27.20B$27.43B$26.96B$27.09B$26.98B$24.13B$24.62B
Operating cash flow$24.53B$24.27B$22.79B$21.19B$23.41B$24.68B$23.42B$22.20B$21.06B$18.77B
Free cash flow$19.31B$18.06B$17.78B$17.18B$19.76B$21.34B$19.92B$18.53B$17.78B$15.54B
Diluted shares2,429.4M2,429.4M2,560.4M2,663.9M2,674.0M2,670.7M2,684.3M2,728.7M2,745.3M2,788.9M

Balance sheet

Period endDec 28Dec 29Dec 31Jan 1Jan 2Jan 3
Cash & equivalents$19.71B$24.11B$21.86B$12.89B$14.49B$13.98B
Short-term investments$393.0M$417.0M$1.07B$9.39B$17.12B$11.20B
Total debt$47.93B$36.63B$29.33B$39.64B$33.75B$35.27B
Total assets$199.21B$180.10B$167.56B$187.38B$182.02B$174.89B
Total liabilities$117.67B$108.61B$98.78B$110.57B$108.00B$111.62B
Shareholders' equity$81.54B$71.49B$68.77B$76.80B$74.02B$63.28B

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology